Ischemic stroke continues to rank among the top causes of death and long-term disability globally. While advances in acute treatments like clot retrieval and thrombolysis have improved outcomes, the ...

The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...

Blood clotting disorders can be inherited or acquired. Some types cause excessive bleeding, while others cause excessive ...

Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...

For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

A pivotal study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...

Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Older adults who are admitted to the hospital with their first ischemic stroke who have poor nutritional status upon admission have a higher risk of post-stroke myocardial injury, a study shows.